Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sufentanil - Talphera

Next Previous
Drug Profile

Sufentanil - Talphera

Alternative Names: ARX 01; ARX-02; ARX-04; ARX-F01; ARX-F02; DSUVIA; DZUVEO; SST system; Sublingual sufentanil; Sufentanil sublingual; Sufentanil sublingual - NanoTab; Sufentanil sublingual tablet; Sufentanil sublingual tablet system; Zalviso

Latest Information Update: 11 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AcelRx Pharmaceuticals
  • Developer Grunenthal; Talphera
  • Class Amides; General anaesthetics; Opioid analgesics; Piperidines; Small molecules; Thiophenes
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Acute pain; Cancer pain; Postoperative pain

Highest Development Phases

  • Marketed Acute pain
  • Suspended Cancer pain

Most Recent Events

  • 09 Jan 2024 AcelRx Pharmaceuticals is now called Talphera
  • 15 May 2023 9388997 - No updates, divestment info already covered
  • 05 Apr 2023 Alora Pharmaceuticals closes in-licensing of sufentanil from AcelRx Pharmaceuticals
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top